Company Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.
The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market.
The company is headquartered in Malvern, Pennsylvania.
| Country | United States |
| IPO Date | Dec 3, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Dr. Shankar Musunuri M.B.A., Ph.D. |
Contact Details
Address: 263 Great Valley Parkway Malvern, Pennsylvania United States | |
| Website | https://www.ocugen.com |
Stock Details
| Ticker Symbol | OCGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372299 |
| CUSIP Number | 67577C105 |
| ISIN Number | US67577C1053 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, Chief Executive Officer & Chairman |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer |
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director |
| John Kouch J.D. | General Counsel |
| Jyothy Pillai M.S. | Vice President & Head of Regulatory & Quality |
| Kristen Craft | Head of People & Culture |
| Michael Shine M.B.A. | Senior Vice President of Commercial |
| Ramesh Ramachandran C.M.A., CPA, M.B.A. | Principal Financial Officer & Principal Accounting Officer |
| Tiffany J. Hamilton M.B.A. | AVice President & Head of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 03, 2024 | 8-K | Current Report |
| Dec 02, 2024 | 4 | Filing |
| Nov 26, 2024 | 4 | Filing |
| Nov 15, 2024 | 3 | Filing |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 08, 2024 | 8-K | Current Report |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |